Published in N Engl J Med on March 06, 2003
Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med (2009) 10.01
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 7.47
Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93
Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) (2008) 5.82
Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut (2010) 4.01
Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA (2005) 3.88
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
Primary prevention of colorectal cancer. Gastroenterology (2010) 3.20
Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? Hum Genet (2007) 3.13
The role of aspirin in cancer prevention. Nat Rev Clin Oncol (2012) 2.94
Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology (2007) 2.73
The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene (2009) 2.72
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) (2009) 2.46
Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32
Can we safely target the WNT pathway? Nat Rev Drug Discov (2014) 2.31
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med (2007) 2.23
Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) (2011) 2.03
Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed) (2010) 1.87
Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol (2004) 1.76
Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer (2011) 1.76
Genotype-phenotype correlations in Peutz-Jeghers syndrome. J Med Genet (2004) 1.73
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis (2007) 1.68
A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) (2011) 1.64
Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst (2013) 1.63
The inflammatory microenvironment in colorectal neoplasia. PLoS One (2011) 1.62
Future directions in cancer prevention. Nat Rev Cancer (2012) 1.62
Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors. Breast Cancer Res Treat (2008) 1.60
Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci U S A (2003) 1.56
Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer (2012) 1.54
A perfect correlate does not a surrogate make. BMC Med Res Methodol (2003) 1.45
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res (2010) 1.44
Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev (2008) 1.42
Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. BMJ (2004) 1.41
The role of aspirin in women's health. Int J Womens Health (2011) 1.39
Molecular targets for cancer chemoprevention. Nat Rev Drug Discov (2009) 1.38
Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. Gastroenterology (2015) 1.35
Animal models of colitis-associated carcinogenesis. J Biomed Biotechnol (2011) 1.33
Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett (2008) 1.32
Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2. Proc Natl Acad Sci U S A (2003) 1.30
5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut (2005) 1.29
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst (2014) 1.28
Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells. Biochem J (2006) 1.28
GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. Mol Cancer Res (2010) 1.28
Diagnosis and treatment of Gardner syndrome with gastric polyposis: a case report and review of the literature. World J Gastroenterol (2008) 1.27
Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat Rev Clin Oncol (2012) 1.26
Drug repurposing in oncology-patient and health systems opportunities. Nat Rev Clin Oncol (2015) 1.25
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene (2013) 1.23
Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer (2005) 1.21
Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut (2010) 1.20
Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer (2009) 1.19
Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol (2012) 1.17
NF-kappaB in carcinoma therapy and prevention. Expert Opin Ther Targets (2008) 1.16
Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol (2006) 1.13
The Repurposing Drugs in Oncology (ReDO) Project. Ecancermedicalscience (2014) 1.08
Aspirin and the prevention of colorectal cancer. N Engl J Med (2003) 1.08
Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. Cancer Prev Res (Phila) (2011) 1.08
Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev (2014) 1.07
Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch (2004) 1.07
Coxibs and serious adverse cardiovascular events: a class-effect? J R Soc Med (2004) 1.07
Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. Ann Surg (2005) 1.07
Infection, inflammation, and gastrointestinal cancer. Gut (2005) 1.07
mPGES-1 as a target for cancer suppression: A comprehensive invited review "Phospholipase A2 and lipid mediators". Biochimie (2010) 1.07
Aspirin inhibits colon cancer cell and tumor growth and downregulates specificity protein (Sp) transcription factors. PLoS One (2012) 1.06
Targeting polyamines and inflammation for cancer prevention. Recent Results Cancer Res (2011) 1.06
Myeloid-derived suppressor cells: the dark knight or the joker in viral infections? Immunol Rev (2013) 1.05
Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst (2009) 1.05
A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. Pharmacogenomics J (2008) 1.04
The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila) (2011) 1.02
Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4. Nat Commun (2014) 1.01
An inflammatory mediator, prostaglandin E2, in colorectal cancer. Cancer J (2013) 1.01
Cell proliferation depends on mitochondrial Ca2+ uptake: inhibition by salicylate. J Physiol (2005) 1.00
Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. Cancer Prev Res (Phila) (2011) 1.00
Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma. Gut (2005) 1.00
Common colorectal cancer risk variants in SMAD7 are associated with survival among prediagnostic nonsteroidal anti-inflammatory drug users: a population-based study of postmenopausal women. Genes Chromosomes Cancer (2011) 0.99
Beyond standard adjuvant therapy for colon cancer: role of nonstandard interventions. Semin Oncol (2011) 0.97
NSAIDs and colorectal cancer prevention. J Gastroenterol (2009) 0.96
Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol (2011) 0.96
Molecular pathways: aspirin and Wnt signaling-a molecularly targeted approach to cancer prevention and treatment. Clin Cancer Res (2014) 0.96
Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma. Br J Cancer (2005) 0.96
Ethnic and racial factors influencing well-being, perceived pain, and physical function after primary total joint arthroplasty. Clin Orthop Relat Res (2011) 0.95
Aspirin and colorectal cancer: back to the future. Clin Cancer Res (2013) 0.95
Obesity is associated with an increased prevalence of advanced adenomatous colon polyps in a male veteran population. Dig Dis Sci (2009) 0.95
Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo. Neoplasia (2012) 0.95
Long-term aspirin use and colorectal cancer risk: a cohort study in Sweden. Br J Cancer (2006) 0.95
Expression of 5-lipoxygenase in human colorectal cancer. World J Gastroenterol (2006) 0.95
Age distribution, polyps and rectal cancer in the Egyptian population-based cancer registry. World J Gastroenterol (2012) 0.94
Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev (2010) 0.94
"Girls on the Move" intervention protocol for increasing physical activity among low-active underserved urban girls: a group randomized trial. BMC Public Health (2013) 0.93
Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas. J Natl Cancer Inst (2009) 0.92
Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial. Cancer Epidemiol Biomarkers Prev (2009) 0.92
Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence. World J Gastroenterol (2008) 0.91
Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer. BMC Cancer (2009) 0.91
Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives. Pharmacogenomics (2007) 0.90
Body mass index and colorectal cancer prognosis: a systematic review and meta-analysis. Tech Coloproctol (2016) 0.90
Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions. Clin Colorectal Cancer (2011) 0.90
Potential targets for colorectal cancer prevention. Int J Mol Sci (2013) 0.89
Role of vitamin and mineral supplementation and aspirin use in cancer survivors. J Clin Oncol (2010) 0.89
Racial differences in colorectal cancer incidence and mortality in the Women's Health Initiative. Cancer Epidemiol Biomarkers Prev (2011) 0.89
Histone deacetylase 3 antagonizes aspirin-stimulated endothelial nitric oxide production by reversing aspirin-induced lysine acetylation of endothelial nitric oxide synthase. Circ Res (2010) 0.89
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med (2005) 15.46
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ (2010) 10.85
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA (2007) 7.93
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol (2004) 7.36
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA (2008) 7.13
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol (2008) 6.23
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol (2010) 5.08
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol (2009) 5.05
National Cancer Institute Patient Navigation Research Program: methods, protocol, and measures. Cancer (2008) 4.64
Association between hospital and surgeon procedure volume and the outcomes of total knee replacement. J Bone Joint Surg Am (2004) 4.42
Rates and outcomes of primary and revision total hip replacement in the United States medicare population. J Bone Joint Surg Am (2003) 4.38
Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology (2005) 4.31
Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol (2010) 4.30
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol (2012) 4.22
Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2005) 4.10
Approaching health disparities from a population perspective: the National Institutes of Health Centers for Population Health and Health Disparities. Am J Public Health (2008) 3.98
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol (2012) 3.73
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet (2007) 3.66
Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA (2007) 3.44
Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst (2003) 3.44
Incidence rates of dislocation, pulmonary embolism, and deep infection during the first six months after elective total hip replacement. J Bone Joint Surg Am (2003) 3.33
Constipation and a low-fiber diet are not associated with diverticulosis. Clin Gastroenterol Hepatol (2013) 3.31
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol (2014) 3.16
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst (2009) 3.15
Calcium intake and hip fracture risk in men and women: a meta-analysis of prospective cohort studies and randomized controlled trials. Am J Clin Nutr (2007) 3.14
Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev (2008) 3.11
Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst (2013) 3.06
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Association of hospital and surgeon volume of total hip replacement with functional status and satisfaction three years following surgery. Arthritis Rheum (2003) 2.98
MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res (2011) 2.95
Identification of Lynch syndrome among patients with colorectal cancer. JAMA (2012) 2.77
Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med (2008) 2.74
Accuracy of Medicare claims data for rheumatologic diagnoses in total hip replacement recipients. J Clin Epidemiol (2003) 2.72
One-year risk for advanced colorectal neoplasia: U.S. versus U.K. risk-stratification guidelines. Ann Intern Med (2012) 2.70
Epidemiology of total knee replacement in the United States Medicare population. J Bone Joint Surg Am (2005) 2.67
Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst (2009) 2.64
Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology (2012) 2.57
Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol (2010) 2.57
Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst (2009) 2.56
A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology (2008) 2.56
Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol (2012) 2.56
Pathophysiology and treatment of hot flashes. Mayo Clin Proc (2002) 2.56
Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer. Clin Gastroenterol Hepatol (2010) 2.50
Colorectal cancers soon after colonoscopy: a pooled multicohort analysis. Gut (2013) 2.50
Alcohol consumption before and after breast cancer diagnosis: associations with survival from breast cancer, cardiovascular disease, and other causes. J Clin Oncol (2013) 2.46
An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol (2004) 2.45
The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer (2010) 2.43
Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol (2013) 2.43
Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology (2007) 2.39
Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. Lancet (2013) 2.37
Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol (2002) 2.33
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol (2003) 2.32
Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3. J Natl Cancer Inst (2007) 2.31
Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut (2010) 2.30
Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol (2010) 2.28
The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality. J Natl Cancer Inst Monogr (2010) 2.26
Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol (2012) 2.22
Telomere length varies by DNA extraction method: implications for epidemiologic research. Cancer Epidemiol Biomarkers Prev (2013) 2.14
Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res (2008) 2.13
NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw (2010) 2.13
Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev (2008) 2.12
Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst (2008) 2.11
Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol (2002) 2.09
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol (2007) 2.09
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Development of common data elements: the experience of and recommendations from the early detection research network. Int J Med Inform (2003) 2.04
Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res (2007) 2.03
Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) (2011) 2.03
Variants on 9p24 and 8q24 are associated with risk of colorectal cancer: results from the Colon Cancer Family Registry. Cancer Res (2007) 2.02
Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. J Natl Cancer Inst (2010) 1.99
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer (2007) 1.94
Survival after hip fracture. Osteoporos Int (2005) 1.93
Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiol Biomarkers Prev (2009) 1.88
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol (2004) 1.83
Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res (2005) 1.81
Association of hospital and surgeon procedure volume with patient-centered outcomes of total knee replacement in a population-based cohort of patients age 65 years and older. Arthritis Rheum (2007) 1.78
Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol (2008) 1.77
Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol (2006) 1.76
Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers Prev (2008) 1.73
Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA (2008) 1.73
Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial. J Natl Cancer Inst (2007) 1.73
Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). Cancer Causes Control (2003) 1.73
Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev (2009) 1.72
Characteristics and survival of interval and sporadic colorectal cancer patients: a nationwide population-based cohort study. Am J Gastroenterol (2013) 1.71
Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut (2011) 1.70
Effect of calcium supplementation on the risk of large bowel polyps. J Natl Cancer Inst (2004) 1.67
Twelve-year risk of revision after primary total hip replacement in the U.S. Medicare population. J Bone Joint Surg Am (2012) 1.67
Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol (2004) 1.66
Colon and rectal cancer survival by tumor location and microsatellite instability: the Colon Cancer Family Registry. Dis Colon Rectum (2013) 1.65
Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila) (2012) 1.65
Genome-wide association study identifies chromosome 10q24.32 variants associated with arsenic metabolism and toxicity phenotypes in Bangladesh. PLoS Genet (2012) 1.64